Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | ECE1 | P42892 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323941 | 0.92 | ACE (0.56) | MMEECE1ACECTSLCTSK | |
| SCHEMBL13323970 | 0.92 | MME (0.55) | MMEECE1ACECTSLSIRT2 | |
| SCHEMBL13323943 | 0.90 | MME (0.56) | MMEECE1ACECTSLCTSK | |
| SCHEMBL13323958 | 0.88 | CTSK (0.51) | MMEECE1CTSLSIRT2SIRT1 | |
| SCHEMBL13323962 | 0.88 | MME (0.54) | MMEECE1ACECTSLCTSK | |
| SCHEMBL13323973 | 0.88 | SIRT2 (0.59) | MMEECE1CTSLSIRT2SIRT1 | |
| SCHEMBL14077187 | 0.86 | CTSK (0.52) | MMEECE1CTSLCTSKCAPN1 | |
| SCHEMBL13324008 | 0.86 | MME (0.50) | MMEECE1ACECTSLSIRT2 | |
| SCHEMBL13323947 | 0.86 | CTSL (0.57) | MMEECE1ACECTSLCTSK | |
| SCHEMBL13323984 | 0.86 | SIRT2 (0.50) | MMEECE1CTSLSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | MME 2392/4885ECE1 3200/4885ACE 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.